SOURCE: Skystar Bio-Pharmaceuticals

Skystar Bio-Pharmaceuticals

December 22, 2015 10:16 ET

Skystar Bio-Pharmaceutical Company Update

XI'AN, CHINA--(Marketwired - Dec 22, 2015) - Skystar Bio-Pharmaceutical Company (OTCQB: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that while the Company trades on the over-the-counter market, it has made progress with its audits.

Following the filing and acceptance of its delinquent quarterly and fiscal year end reports with the Securities Exchange Commission pursuant to the Exchange Act of 1934, as amended, Skystar intend to continue to follow applicable Nasdaq listing standards, notwithstanding its delisting.

Skystar will continue to provide both operational and financial updates to the market periodically and intends to apply for a Nasdaq listing at a future date and time.

About Skystar Bio-Pharmaceutical Company

Skystar is a China-based developer, manufacturer and distributor of veterinary healthcare and medical care products. Skystar has four product lines: veterinary medicines, probiotics, vaccines and feed additives formulated and packaged in house across several modern manufacturing and distributions facilities. Skystar's distribution network includes almost 3,000 distribution agents of which 360 are franchised stores with exclusivity agreements covering 29 provinces throughout China. For additional information, please visit

Safe Harbor Statements

When used in this release, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Forward-looking statements include, without limitation, the Company's ability to complete its IgG kit effort as well as other related efforts at the Huxian facilities, the Company's ability to timely, effectively and accurately assess the efficacy and commercial potential of any technologies that may results from such R&D efforts, the Company's ability to timely and effectively commercialize any such technologies. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact Information

  • Contact:

    Skystar Bio-Pharmaceutical Company
    Scott Cramer
    Director - Corporate Development & U.S. Representative
    (407) 645-4433